Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery

Thomas U. Marron; Matthew D. Galsky; Bachir Taouli; Maria Isabel Fiel; Stephen Ward; Edward Kim; David Yankelevitz; Deborah Doroshow; Emma Guttman; Benjamin Ungar; Saurabh Mehandru; Benjamin J. Golas; Daniel Labow; John Sfakianos; Sujit S. Nair; Dimple Chakravarty; Michael Buckstein; Xiaoyu Song; Effi Kenigsberg; Sacha Gnjatic; Brian D. Brown; Joseph Sparano; Ashutosh Tewari; Myron Schwartz; Nina Bhardwaj; Miriam Merad

doi:10.1038/s41591-022-01681-x

Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery

Brian D. Brown, Joseph Sparano, Ashutosh Tewari, Myron Schwartz, Nina Bhardwaj, Miriam Merad

Research output: Contribution to journal › Comment/debate

22 Scopus citations

Original language	English
Pages (from-to)	626-629
Number of pages	4
Journal	Nature Medicine
Volume	28
Issue number	4
DOIs	https://doi.org/10.1038/s41591-022-01681-x
State	Published - Apr 2022

Access to Document

10.1038/s41591-022-01681-x

Cite this

Marron, T. U., Galsky, M. D., Taouli, B., Fiel, M. I., Ward, S., Kim, E., Yankelevitz, D., Doroshow, D., Guttman, E., Ungar, B., Mehandru, S., Golas, B. J., Labow, D., Sfakianos, J., Nair, S. S., Chakravarty, D., Buckstein, M., Song, X., Kenigsberg, E., ... Merad, M. (2022). Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery. Nature Medicine, 28(4), 626-629. https://doi.org/10.1038/s41591-022-01681-x

@article{779c9ee4df58471e90be2d1b2d4c6938,

title = "Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery",

author = "Marron, \{Thomas U.\} and Galsky, \{Matthew D.\} and Bachir Taouli and Fiel, \{Maria Isabel\} and Stephen Ward and Edward Kim and David Yankelevitz and Deborah Doroshow and Emma Guttman and Benjamin Ungar and Saurabh Mehandru and Golas, \{Benjamin J.\} and Daniel Labow and John Sfakianos and Nair, \{Sujit S.\} and Dimple Chakravarty and Michael Buckstein and Xiaoyu Song and Effi Kenigsberg and Sacha Gnjatic and Brown, \{Brian D.\} and Joseph Sparano and Ashutosh Tewari and Myron Schwartz and Nina Bhardwaj and Miriam Merad",

note = "Funding Information: The authors have no competing interests in regards to the content of this commentary. They receive industry funding from partners to fund window studies, including Regeneron, Bristol Myers Squibb, Boehringer Ingelheim, Oncovir and Merck.",

year = "2022",

month = apr,

doi = "10.1038/s41591-022-01681-x",

language = "English",

volume = "28",

pages = "626--629",

journal = "Nature Medicine",

issn = "1078-8956",

publisher = "Nature Research",

number = "4",

}

Marron, TU , Galsky, MD , Taouli, B , Fiel, MI , Ward, S , Kim, E, Yankelevitz, D, Doroshow, D , Guttman, E , Ungar, B , Mehandru, S, Golas, BJ, Labow, D , Sfakianos, J, Nair, SS, Chakravarty, D, Buckstein, M, Song, X, Kenigsberg, E, Gnjatic, S , Brown, BD , Sparano, J , Tewari, A , Schwartz, M , Bhardwaj, N & Merad, M 2022, 'Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery', Nature Medicine, vol. 28, no. 4, pp. 626-629. https://doi.org/10.1038/s41591-022-01681-x

TY - JOUR

T1 - Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery

AU - Marron, Thomas U.

AU - Galsky, Matthew D.

AU - Taouli, Bachir

AU - Fiel, Maria Isabel

AU - Ward, Stephen

AU - Kim, Edward

AU - Yankelevitz, David

AU - Doroshow, Deborah

AU - Guttman, Emma

AU - Ungar, Benjamin

AU - Mehandru, Saurabh

AU - Golas, Benjamin J.

AU - Labow, Daniel

AU - Sfakianos, John

AU - Nair, Sujit S.

AU - Chakravarty, Dimple

AU - Buckstein, Michael

AU - Song, Xiaoyu

AU - Kenigsberg, Effi

AU - Gnjatic, Sacha

AU - Brown, Brian D.

AU - Sparano, Joseph

AU - Tewari, Ashutosh

AU - Schwartz, Myron

AU - Bhardwaj, Nina

AU - Merad, Miriam

N1 - Funding Information: The authors have no competing interests in regards to the content of this commentary. They receive industry funding from partners to fund window studies, including Regeneron, Bristol Myers Squibb, Boehringer Ingelheim, Oncovir and Merck.

PY - 2022/4

Y1 - 2022/4

UR - https://www.scopus.com/pages/publications/85127251243

U2 - 10.1038/s41591-022-01681-x

DO - 10.1038/s41591-022-01681-x

M3 - Comment/debate

C2 - 35347282

AN - SCOPUS:85127251243

SN - 1078-8956

VL - 28

SP - 626

EP - 629

JO - Nature Medicine

JF - Nature Medicine

IS - 4

ER -